From Wikipedia, the free encyclopedia
  (Redirected from RIGVIR)
Jump to navigation Jump to search

ECHO-7 (trade name Rigvir) is a wild type member of the echovirus family.[1] It was formerly approved as a virotherapy medication by the State Agency of Medicines of the Republic of Latvia (2004–19).[2] In March 2019, the distribution in Latvia was stopped by the State Agency of Medicines, after laboratory tests found that the amount of ECHO-7 virus was in much smaller amounts than claimed.[3] On May 31, 2019, the State Agency of Medicines suspended the registration licence of ECHO-7.[4]


The potential use of echovirus as an oncolytic virus to treat cancer was discovered by Latvian scientist Aina Muceniece in the 1960s and 1970s.[1]


The data used to register the drug in Latvia is not sufficient to obtain approval to use it in the US, Europe, or Japan.[1][5] As of 2017 there was no good evidence that ECHO-7 is an effective cancer treatment.[6][7]

Oncologists and other medical experts in Latvia have repeatedly expressed the concern for the lack of clinical trials and evidence of efficacy, as well as unethical advertising.[8] Oncologist David Gorski has written that "There are many aspects to the RIGVIR story that strongly suggest that RIGVIR is probably cancer quackery" citing the "mysterious creator" aspect, the misleading description of the product as "natural" and the use of testimonials to market it.[6]

In February 2017, the Association of Oncologists, Association of Chemotherapists, Association of Rare Diseases of Latvia, and the Head of Pharmacology Department of Riga Stradiņš University submitted a request to the Ministry of Health of Latvia, State Agency of Medicines, and National Health Service requesting the removal of ECHO-7 from the Register of Medicines of Latvia and from the list of state-compensated medicines.[6] A revision of clinical treatment guidelines for melanoma was also requested.[9] The request was based on the analysis of available research and suggests that there is no conclusive evidence for the efficacy of RIGVIR as a cancer treatment.[10] In 2017 the Health Ministry of Latvia responded that RIGVIR would remain on its medicines register, and that in its judgement the risk-benefit ratio for RIGVIR as acceptable.[11] At the end of 2018, Commission of Social and Labor Affairs of Latvian Parliament started a discussion about possible exclusion of RIGVIR from the list of state-compensated medicines and the Register of Medicines of Latvia.[12][13]

On March 19, 2019, the manufacturer of ECHO-7, SIA LATIMA, announced the drug's removal from sale in Latvia, quoting financial and strategic reasons and insufficient profitability.[14] However, several days later an investigative TV show revealed that State Agency of Medicines had run laboratory tests on the vials, and found that the amount of ECHO-7 virus is of a much smaller amount than claimed by the manufacturer. According to agency's lab director, "It's like buying what you think is lemon juice, but finding that what you have is lemon-flavored water". In March 2019, the distribution of ECHO-7 in Latvia has been stopped.[3] ECHO-7 has also been removed from the list of state-reimbursed medications.[15] On May 31, 2019, the registration licence of ECHO-7 was suspended in Latvia. [4] Based on the request of some patients, medical institutions, and physicians, despite the suspension of the registration certificate, were allowed to continue use.[16]

According to Solvita Olsena, expert in patient safety at the University of Latvia, people who have used ECHO-7 should contact the police, as facts indicate that a criminal offence has occurred. According to Olsena, police has the duty to protect people; it is a dangerous precedent when people receive medicines that do not contain the substance which should be present.[17] A member of Latvian parliament and advisor to the Prime Minister, Renars Putnins, also has called the entire thing an affair and has asked for an official investigation.[18]


In Latvia manufacturers of ECHO-7 have a history of receiving fines for off-label marketing this anti-cancer drug directly to general public and cancer patients.[8][19][20][21] However, on October 31, 2018 the Regional Administrative Court of Latvia canceled the sanction imposed by the local Health Inspectorate for the unauthorized off-label advertising.[22]

See also[edit]


  1. ^ a b c Babiker, HM; Riaz, IB; Husnain, M; Borad, MJ (2017). "Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma". Oncolytic Virotherapy. 6: 11–18. doi:10.2147/OV.S100072. PMC 5308590. PMID 28224120.
  2. ^ "Medicinal Product Register of Latvia". Retrieved 2018-11-18.
  3. ^ a b "Rigvir cancer treatment at center of fresh controversy".
  4. ^ a b "Apturēta Rigvir reģistrācija; informācija esošajiem pacientiem".
  5. ^ "Feasibility study for registration of medicine RIGVIR with the European Medicine Agency". European Commission. 2016-01-08. Archived from the original on 2016-11-02. Retrieved 2016-11-02. However, further use and commercialisation in the EU is prevented as EU regulations require cancer medicines to be registered centrally through the European Medicine Agency (EMA). National registrations are not considered.
  6. ^ a b c Gorski D (18 September 2017). "Rigvir: Another unproven and dubious cancer therapy to be avoided". Science-Based Medicine.
  7. ^ Gorski, David (25 September 2017). "Ty Bollinger's "The Truth About Cancer" and the unethical marketing of the unproven cancer virotherapy Rigvir". Science-Based Medicine.
  8. ^ a b Ritums, Eduards (October 2016). "When science takes a back seat". Archived from the original on 2018-07-02. Retrieved 2017-08-08.
  9. ^ Stirāne, Dace. "Latvia to review state compensation for Rigvir anti-cancer drug". Public broadcasting of Latvia.
  10. ^ Nagle, Gunita (2017-02-07). "Onkologi prasa izņemt "Rigvir" no Zāļu reģistra".
  11. ^ "Health Ministry of Latvia statement regarding the registration/approval of medicinal products" (in Latvian). Retrieved 16 October 2017.
  12. ^ "Rigvir may be excluded from the list of state-compensated medicines" (in Russian). Retrieved 18 December 2018.
  13. ^ "Validity of Rigvir registration discussed" (in Latvian). Retrieved 18 December 2018.
  14. ^ "Rigvir medication distribution in Latvia halted temporarily". 2019-03-19.
  15. ^ "Distribution of Rigvir anti-cancer medicine suspended".
  16. ^ "Apturēta Rigvir reģistrācija; informācija esošajiem pacientiem | Zāļu valsts aģentūra". Retrieved 11 June 2019.
  17. ^ "Zāļu ražotājs "Rigvir" maldinājis ne tikai valsts institūcijas, bet arī pacientus, uzskata VM".
  18. ^ "Calls for official probe over Rigvir cancer treatment scandal".
  19. ^ "Veselības inspekcija | Pieņemts lēmums par naudas soda piemērošanu zāļu Rigvir reģistrācijas apliecības īpašniekam par negodīgu komercpraksi".
  20. ^ "Veselības inspekcija par neatļautu 'Rigvir' reklamēšanu piemērojusi naudas sodu SIA 'Latima'".
  21. ^ "Neatceļ naudas sodu par neatļautu 'Rigvir' reklamēšanu".
  22. ^ "Tiesa atceļ Veselības inspekcijas piemēroto naudas sodu par neatļautu Rigvir reklamēšanu".